HighTower Advisors LLC Decreases Position in Qiagen N.V. $QGEN

Key Points

• HighTower Advisors LLC reduced its stake in Qiagen N.V. by 43% in the first quarter, now holding 10,333 shares valued at $415,000 after selling 7,805 shares.
• Deutsche Bank AG increased its holdings in Qiagen by 57.5%, now owning 4,491,131 shares worth approximately $180.3 million.
• Qiagen reported a revenue increase of 7.7% year-over-year, with EPS meeting expectations at $0.60 per share for the last quarter.

HighTower Advisors LLC lowered its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 43.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,333 shares of the company's stock after selling 7,805 shares during the quarter. HighTower Advisors LLC's holdings in Qiagen were worth $415,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in QGEN. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Qiagen in the 4th quarter valued at about $95,746,000. Deutsche Bank AG increased its stake in shares of Qiagen by 57.5% during the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after purchasing an additional 1,639,621 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Qiagen during the 1st quarter worth approximately $44,078,000. Envestnet Asset Management Inc. purchased a new stake in shares of Qiagen during the 1st quarter worth approximately $13,463,000. Finally, Northern Trust Corp increased its stake in shares of Qiagen by 29.5% during the 4th quarter. Northern Trust Corp now owns 1,250,712 shares of the company's stock worth $55,694,000 after purchasing an additional 285,265 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Barclays initiated coverage on shares of Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Bank of America lifted their price objective on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Cowen reiterated a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Wall Street Zen lowered shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Finally, UBS Group lifted their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $49.69.

Qiagen Price Performance

Shares of NYSE QGEN traded up $0.18 during mid-day trading on Thursday, reaching $46.88. 429,046 shares of the company were exchanged, compared to its average volume of 1,393,184. Qiagen N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $10.42 billion, a PE ratio of 27.69, a PEG ratio of 2.57 and a beta of 0.64. The company's 50 day moving average price is $48.68 and its 200 day moving average price is $44.25.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.60. The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm's revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.